Evaluation of the effect of L-carnitine on the prevention of drug induced hepatitis
Phase 3
Recruiting
- Conditions
- Acute Lymphoblastic Leukemia.Acute lymphoblastic leukemia [ALL]C91.0
- Registration Number
- IRCT20190202042583N4
- Lead Sponsor
- Mazandaran University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 38
Inclusion Criteria
getting acute lymphoblastic leukemia
normal enzyme levels at the beginning of the study
Exclusion Criteria
underlying liver disease
underlying metabolic disease involving the liver (galactosemia-tyrosinemia-...)
Viral hepatitis
Use of hepatotoxic drugs
Elevation of bilirubin or liver transaminases above normal values before the start of the study
Contraindication or allergy to L-carnitine
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Drug induced Hepatitis. Timepoint: before receiving the drug to 14 days after receiving PEG-Asparaginase. Method of measurement: by the clinical supervisor accompanying the plan and according to the criteria of the World Health Organization.
- Secondary Outcome Measures
Name Time Method